Vascular endothelial growth factor (VEGF) plays a critical role in many pathologies, including vascular disease and cancer.1–5 Despite this role, VEGF-targeted therapies are not clinically effective for many patients.6,7 As such, there is an urgent need to develop a better understanding of how VEGF-promoted pathologies can be controlled, mechanistically, to improve the efficiency and specificity of current VEGF treatments. The gene discussed is VEGFA; the disease is cancer.